Viridian Therapeutics, Inc.\de
A biotechnology company developing new treatments for thyroid eye disease, a rare autoimmune condition that makes the tissues behind the eye swell and bulge. Its lead experimental medicine, veligrotug, is an antibody designed to block the protein driving that swelling. The company was formed under its current name in 2022, taking "Viridian" from the green pigment, a nod to fresh growth.
Granted 14.1K · Bought 3.23M
Bought 1.81M
Bought 200.0K
Granted 50.0K · Sold 250.0K
Granted 250.0K · Bought 9.5K
Bought 21.4K
Granted 59.5K · Sold 89.5K
Bought 5.0K
Sold 2.3K
Granted 89.0K · Sold 89.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC +2 co-filersDirector, 10% owner · 5 transactions | — | 9.01M | 14.1K | 3.23M | — |
| Fairmount Funds Management LLC +4 co-filersDirector, 10% owner, Director · 5 transactions | +250.7% | 1.85Mas of Mar 2024 | — | 1.81M | — |
| FHMLSP, L.L.C. +2 co-filers10% owner · 1 transaction | +15.3% | 1.51Mas of Sep 2021 | — | 200.0K | — |
| Violin JonathanChief Executive Officer, Director · 13 transactions | +759.7% | 430.9Kas of Feb 2023 | 50.0K | — | 250.0K |
| Myers Scott DunsethChief Executive Officer, Director · 3 transactions | — | 259.5Kas of Apr 2023 | 250.0K | 9.5K | — |
| Mahoney Stephen F.President and CEO, Director · 2 transactions | — | 33.3K | — | 21.4K | — |
| Meisner LaraChief Legal Officer · 28 transactions | — | 30.0Kas of Jun 2023 | 59.5K | — | 89.5K |
| Beetham Thomas W.Chief Operating Officer · 2 transactions | — | 13.4K | — | 5.0K | — |
| Harmon SethChief Financial Officer · 1 transaction | — | 1.7K | — | — | — |
| Tousignant JenniferChief Legal Officer · 2 transactions | — | 610 | — | — | 2.3K |
| Katz BarrettChief Medical Officer · 8 transactions | — | 0as of Jan 2023 | 89.0K | — | 89.0K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +4.85M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.